#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1.
1-1	0-2	1.	_	_	_	_

#Text=Introduction
2-1	3-15	Introduction	abstract	new	_	_

#Text=Cholesterol is predominantly synthesized de novo in the liver with lesser amounts obtained from the diet .
3-1	16-27	Cholesterol	substance	new	coref	5-12
3-2	28-30	is	_	_	_	_
3-3	31-44	predominantly	_	_	_	_
3-4	45-56	synthesized	_	_	_	_
3-5	57-59	de	_	_	_	_
3-6	60-64	novo	_	_	_	_
3-7	65-67	in	_	_	_	_
3-8	68-71	the	object[3]	new[3]	coref	5-26[25_3]
3-9	72-77	liver	object[3]	new[3]	_	_
3-10	78-82	with	object[3]	new[3]	_	_
3-11	83-89	lesser	object[3]|quantity[4]	new[3]|new[4]	_	_
3-12	90-97	amounts	object[3]|quantity[4]	new[3]|new[4]	_	_
3-13	98-106	obtained	_	_	_	_
3-14	107-111	from	_	_	_	_
3-15	112-115	the	abstract[5]	new[5]	_	_
3-16	116-120	diet	abstract[5]	new[5]	_	_
3-17	121-122	.	_	_	_	_

#Text=Dietary intake , de novo synthesis , metabolism and excretion , combine to balance circulating cholesterol levels ensuring extra-hepatic tissues are sufficiently equipped to produce a range of metabolites including steroid hormones , bile acids and seco-steroids .
4-1	123-130	Dietary	substance|event[7]	new|new[7]	_	_
4-2	131-137	intake	event[7]	new[7]	_	_
4-3	138-139	,	_	_	_	_
4-4	140-142	de	abstract[8]	new[8]	_	_
4-5	143-147	novo	abstract[8]	new[8]	_	_
4-6	148-157	synthesis	abstract[8]	new[8]	_	_
4-7	158-159	,	_	_	_	_
4-8	160-170	metabolism	abstract	new	coref	6-10[38_0]
4-9	171-174	and	_	_	_	_
4-10	175-184	excretion	substance	new	_	_
4-11	185-186	,	_	_	_	_
4-12	187-194	combine	_	_	_	_
4-13	195-197	to	_	_	_	_
4-14	198-205	balance	_	_	_	_
4-15	206-217	circulating	abstract[11]	new[11]	_	_
4-16	218-229	cholesterol	abstract[11]	new[11]	_	_
4-17	230-236	levels	abstract[11]	new[11]	_	_
4-18	237-245	ensuring	_	_	_	_
4-19	246-259	extra-hepatic	place[12]	new[12]	coref	8-20[0_12]
4-20	260-267	tissues	place[12]	new[12]	_	_
4-21	268-271	are	_	_	_	_
4-22	272-284	sufficiently	_	_	_	_
4-23	285-293	equipped	_	_	_	_
4-24	294-296	to	_	_	_	_
4-25	297-304	produce	_	_	_	_
4-26	305-306	a	_	_	_	_
4-27	307-312	range	_	_	_	_
4-28	313-315	of	_	_	_	_
4-29	316-327	metabolites	substance[13]	new[13]	_	_
4-30	328-337	including	substance[13]	new[13]	_	_
4-31	338-345	steroid	substance[13]|object|substance[15]	new[13]|new|new[15]	_	_
4-32	346-354	hormones	substance[13]|substance[15]	new[13]|new[15]	_	_
4-33	355-356	,	substance[13]	new[13]	_	_
4-34	357-361	bile	substance[13]|substance[16]	new[13]|new[16]	coref	14-47[117_16]
4-35	362-367	acids	substance[13]|substance[16]	new[13]|new[16]	_	_
4-36	368-371	and	substance[13]	new[13]	_	_
4-37	372-385	seco-steroids	substance[13]|substance	new[13]|new	_	_
4-38	386-387	.	_	_	_	_

#Text=Side-chain hydroxycholesterols ( scOHCs ) are typically formed through hydroxylation of cholesterol by specialized members of the Cytochrome P450 family , which bind and activate the Liver X Receptor-alpha ( LXRA ; gene name NR1H3 ) and beta ( LXRB ; gene name NR1H2 ) transcription factors .
5-1	388-398	Side-chain	substance[18]	new[18]	_	_
5-2	399-418	hydroxycholesterols	substance[18]	new[18]	_	_
5-3	419-420	(	_	_	_	_
5-4	421-427	scOHCs	object	new	coref	8-15[53_0]
5-5	428-429	)	_	_	_	_
5-6	430-433	are	_	_	_	_
5-7	434-443	typically	_	_	_	_
5-8	444-450	formed	_	_	_	_
5-9	451-458	through	_	_	_	_
5-10	459-472	hydroxylation	substance[20]	new[20]	_	_
5-11	473-475	of	substance[20]	new[20]	_	_
5-12	476-487	cholesterol	substance[20]|substance	new[20]|giv	coref	6-8
5-13	488-490	by	_	_	_	_
5-14	491-502	specialized	person[22]	new[22]	_	_
5-15	503-510	members	person[22]	new[22]	_	_
5-16	511-513	of	person[22]	new[22]	_	_
5-17	514-517	the	person[22]|organization[24]	new[22]|new[24]	_	_
5-18	518-528	Cytochrome	person[22]|organization[24]	new[22]|new[24]	_	_
5-19	529-533	P450	person[22]|person|organization[24]	new[22]|new|new[24]	_	_
5-20	534-540	family	person[22]|organization[24]	new[22]|new[24]	_	_
5-21	541-542	,	_	_	_	_
5-22	543-548	which	_	_	_	_
5-23	549-553	bind	_	_	_	_
5-24	554-557	and	_	_	_	_
5-25	558-566	activate	_	_	_	_
5-26	567-570	the	object[25]	giv[25]	coref	7-11[42_25]
5-27	571-576	Liver	object[25]	giv[25]	_	_
5-28	577-578	X	person[26]	new[26]	_	_
5-29	579-593	Receptor-alpha	person[26]	new[26]	_	_
5-30	594-595	(	_	_	_	_
5-31	596-600	LXRA	abstract	new	coref	7-7
5-32	601-602	;	_	_	_	_
5-33	603-607	gene	_	_	_	_
5-34	608-612	name	_	_	_	_
5-35	613-618	NR1H3	abstract	new	_	_
5-36	619-620	)	_	_	_	_
5-37	621-624	and	_	_	_	_
5-38	625-629	beta	abstract	new	_	_
5-39	630-631	(	_	_	_	_
5-40	632-636	LXRB	abstract	new	coref	7-23
5-41	637-638	;	_	_	_	_
5-42	639-643	gene	abstract[31]	new[31]	_	_
5-43	644-648	name	abstract[31]	new[31]	_	_
5-44	649-654	NR1H2	_	_	_	_
5-45	655-656	)	_	_	_	_
5-46	657-670	transcription	abstract[32]	new[32]	_	_
5-47	671-678	factors	abstract[32]	new[32]	_	_
5-48	679-680	.	_	_	_	_

#Text=LXR target genes are typically involved in cholesterol and fatty acid metabolism .
6-1	681-684	LXR	abstract|abstract[35]	new|new[35]	coref|coref	10-22|10-22
6-2	685-691	target	abstract|abstract[35]	new|new[35]	_	_
6-3	692-697	genes	abstract[35]	new[35]	_	_
6-4	698-701	are	_	_	_	_
6-5	702-711	typically	_	_	_	_
6-6	712-720	involved	_	_	_	_
6-7	721-723	in	_	_	_	_
6-8	724-735	cholesterol	substance	giv	coref	23-41
6-9	736-739	and	_	_	_	_
6-10	740-745	fatty	abstract[38]	giv[38]	coref	23-41[218_38]
6-11	746-750	acid	substance|abstract[38]	new|giv[38]	_	_
6-12	751-761	metabolism	abstract[38]	giv[38]	_	_
6-13	762-763	.	_	_	_	_

#Text=In normal tissue , expression of LXRA is inducible in the liver , intestine , macrophages and adipocytes , whilst expression of LXRB is more ubiquitous .
7-1	764-766	In	_	_	_	_
7-2	767-773	normal	object[39]	new[39]	coref	20-13[172_39]
7-3	774-780	tissue	object[39]	new[39]	_	_
7-4	781-782	,	_	_	_	_
7-5	783-793	expression	abstract[40]	new[40]	_	_
7-6	794-796	of	abstract[40]	new[40]	_	_
7-7	797-801	LXRA	abstract[40]|abstract	new[40]|giv	coref	8-8
7-8	802-804	is	_	_	_	_
7-9	805-814	inducible	_	_	_	_
7-10	815-817	in	_	_	_	_
7-11	818-821	the	object[42]	giv[42]	_	_
7-12	822-827	liver	object[42]	giv[42]	_	_
7-13	828-829	,	_	_	_	_
7-14	830-839	intestine	place	new	_	_
7-15	840-841	,	_	_	_	_
7-16	842-853	macrophages	object	new	_	_
7-17	854-857	and	_	_	_	_
7-18	858-868	adipocytes	object	new	_	_
7-19	869-870	,	_	_	_	_
7-20	871-877	whilst	_	_	_	_
7-21	878-888	expression	abstract[46]	new[46]	_	_
7-22	889-891	of	abstract[46]	new[46]	_	_
7-23	892-896	LXRB	abstract[46]|abstract	new[46]|giv	coref	8-10
7-24	897-899	is	_	_	_	_
7-25	900-904	more	_	_	_	_
7-26	905-915	ubiquitous	_	_	_	_
7-27	916-917	.	_	_	_	_

#Text=As well as differences in expression of LXRA and LXRB , local concentrations of the scOHCs differ considerably between tissues , and relative to each other , sometimes by as much as 1000-fold and variance can also depend on disease status .
8-1	918-920	As	_	_	_	_
8-2	921-925	well	_	_	_	_
8-3	926-928	as	_	_	_	_
8-4	929-940	differences	abstract[48]	new[48]	_	_
8-5	941-943	in	abstract[48]	new[48]	_	_
8-6	944-954	expression	abstract[48]|abstract[49]	new[48]|new[49]	_	_
8-7	955-957	of	abstract[48]|abstract[49]	new[48]|new[49]	_	_
8-8	958-962	LXRA	abstract[48]|abstract[49]|abstract	new[48]|new[49]|giv	coref	14-1
8-9	963-966	and	abstract[48]|abstract[49]	new[48]|new[49]	_	_
8-10	967-971	LXRB	abstract[48]|abstract[49]|abstract	new[48]|new[49]|giv	coref	14-9[98_0]
8-11	972-973	,	_	_	_	_
8-12	974-979	local	animal[52]	new[52]	coref	11-8[70_52]
8-13	980-994	concentrations	animal[52]	new[52]	_	_
8-14	995-997	of	animal[52]	new[52]	_	_
8-15	998-1001	the	animal[52]|object[53]	new[52]|giv[53]	coref	9-3[57_53]
8-16	1002-1008	scOHCs	animal[52]|object[53]	new[52]|giv[53]	_	_
8-17	1009-1015	differ	_	_	_	_
8-18	1016-1028	considerably	_	_	_	_
8-19	1029-1036	between	_	_	_	_
8-20	1037-1044	tissues	place	giv	_	_
8-21	1045-1046	,	_	_	_	_
8-22	1047-1050	and	_	_	_	_
8-23	1051-1059	relative	_	_	_	_
8-24	1060-1062	to	_	_	_	_
8-25	1063-1067	each	_	_	_	_
8-26	1068-1073	other	_	_	_	_
8-27	1074-1075	,	_	_	_	_
8-28	1076-1085	sometimes	_	_	_	_
8-29	1086-1088	by	_	_	_	_
8-30	1089-1091	as	_	_	_	_
8-31	1092-1096	much	_	_	_	_
8-32	1097-1099	as	_	_	_	_
8-33	1100-1109	1000-fold	_	_	_	_
8-34	1110-1113	and	_	_	_	_
8-35	1114-1122	variance	_	_	_	_
8-36	1123-1126	can	_	_	_	_
8-37	1127-1131	also	_	_	_	_
8-38	1132-1138	depend	_	_	_	_
8-39	1139-1141	on	_	_	_	_
8-40	1142-1149	disease	abstract|abstract[56]	new|new[56]	coref|coref|coref|coref	20-33[178_0]|23-11[209_56]|20-33[178_0]|23-11[209_56]
8-41	1150-1156	status	abstract[56]	new[56]	_	_
8-42	1157-1158	.	_	_	_	_

#Text=Furthermore , the different scOHCs have varying capacities to activate LXR-mediated transcription , imposing an element of selective modulation onto signalling .
9-1	1159-1170	Furthermore	_	_	_	_
9-2	1171-1172	,	_	_	_	_
9-3	1173-1176	the	object[57]	giv[57]	coref	20-5[170_57]
9-4	1177-1186	different	object[57]	giv[57]	_	_
9-5	1187-1193	scOHCs	object[57]	giv[57]	_	_
9-6	1194-1198	have	_	_	_	_
9-7	1199-1206	varying	abstract[58]	new[58]	_	_
9-8	1207-1217	capacities	abstract[58]	new[58]	_	_
9-9	1218-1220	to	_	_	_	_
9-10	1221-1229	activate	_	_	_	_
9-11	1230-1242	LXR-mediated	abstract[59]	new[59]	_	_
9-12	1243-1256	transcription	abstract[59]	new[59]	_	_
9-13	1257-1258	,	_	_	_	_
9-14	1259-1267	imposing	_	_	_	_
9-15	1268-1270	an	abstract[60]	new[60]	coref	12-35[85_60]
9-16	1271-1278	element	abstract[60]	new[60]	_	_
9-17	1279-1281	of	abstract[60]	new[60]	_	_
9-18	1282-1291	selective	abstract[60]|abstract[61]	new[60]|new[61]	_	_
9-19	1292-1302	modulation	abstract[60]|abstract[61]	new[60]|new[61]	_	_
9-20	1303-1307	onto	abstract[60]|abstract[61]	new[60]|new[61]	_	_
9-21	1308-1318	signalling	abstract[60]|abstract[61]|abstract	new[60]|new[61]|new	coref	15-12[129_0]
9-22	1319-1320	.	_	_	_	_

#Text=26-OHC ( commonly referred to as 27-OHC ) for example is the most abundant scOHC , but is a relatively weak LXR agonist .
10-1	1321-1327	26-OHC	abstract	new	coref	10-12[65_0]
10-2	1328-1329	(	_	_	_	_
10-3	1330-1338	commonly	_	_	_	_
10-4	1339-1347	referred	_	_	_	_
10-5	1348-1350	to	_	_	_	_
10-6	1351-1353	as	_	_	_	_
10-7	1354-1360	27-OHC	abstract	new	_	_
10-8	1361-1362	)	_	_	_	_
10-9	1363-1366	for	_	_	_	_
10-10	1367-1374	example	_	_	_	_
10-11	1375-1377	is	_	_	_	_
10-12	1378-1381	the	abstract[65]	giv[65]	coref	11-8[0_65]
10-13	1382-1386	most	abstract[65]	giv[65]	_	_
10-14	1387-1395	abundant	abstract[65]	giv[65]	_	_
10-15	1396-1401	scOHC	abstract[65]	giv[65]	_	_
10-16	1402-1403	,	abstract[65]	giv[65]	_	_
10-17	1404-1407	but	abstract[65]	giv[65]	_	_
10-18	1408-1410	is	abstract[65]	giv[65]	_	_
10-19	1411-1412	a	abstract[65]|abstract[67]	giv[65]|new[67]	_	_
10-20	1413-1423	relatively	abstract[65]|abstract[67]	giv[65]|new[67]	_	_
10-21	1424-1428	weak	abstract[65]|abstract[67]	giv[65]|new[67]	_	_
10-22	1429-1432	LXR	abstract[65]|abstract|abstract[67]	giv[65]|giv|new[67]	coref	15-12
10-23	1433-1440	agonist	abstract[65]|abstract[67]	giv[65]|new[67]	_	_
10-24	1441-1442	.	_	_	_	_

#Text=Moreover , there is little difference in scOHC concentrations between breast cancer subtypes .
11-1	1443-1451	Moreover	_	_	_	_
11-2	1452-1453	,	_	_	_	_
11-3	1454-1459	there	_	_	_	_
11-4	1460-1462	is	_	_	_	_
11-5	1463-1469	little	abstract[68]	new[68]	coref	21-23[188_68]
11-6	1470-1480	difference	abstract[68]	new[68]	_	_
11-7	1481-1483	in	abstract[68]	new[68]	_	_
11-8	1484-1489	scOHC	abstract[68]|abstract|animal[70]	new[68]|giv|giv[70]	coref|coref|coref|coref	15-3|15-3[125_70]|15-3|15-3[125_70]
11-9	1490-1504	concentrations	abstract[68]|animal[70]	new[68]|giv[70]	_	_
11-10	1505-1512	between	abstract[68]|animal[70]	new[68]|giv[70]	_	_
11-11	1513-1519	breast	abstract[68]|animal[70]|place|abstract[73]	new[68]|giv[70]|new|new[73]	coref|coref	21-29[192_73]|21-29[192_73]
11-12	1520-1526	cancer	abstract[68]|animal[70]|abstract|abstract[73]	new[68]|giv[70]|new|new[73]	coref	14-25
11-13	1527-1535	subtypes	abstract[68]|animal[70]|abstract[73]	new[68]|giv[70]|new[73]	_	_
11-14	1536-1537	.	_	_	_	_

#Text=Transcriptional activity of the LXRs , like the other members of the Nuclear Receptor ( NR ) superfamily , is not just regulated by ligand bioavailability ; chromatin environment , cross-talk and competition for response element binding with other NRs , as well as cell- and tissue-type dependent expression of cofactors are also key mediators .
12-1	1538-1553	Transcriptional	abstract[74]	new[74]	_	_
12-2	1554-1562	activity	abstract[74]	new[74]	_	_
12-3	1563-1565	of	abstract[74]	new[74]	_	_
12-4	1566-1569	the	abstract[74]|object[75]	new[74]|new[75]	_	_
12-5	1570-1574	LXRs	abstract[74]|object[75]	new[74]|new[75]	_	_
12-6	1575-1576	,	abstract[74]	new[74]	_	_
12-7	1577-1581	like	abstract[74]	new[74]	_	_
12-8	1582-1585	the	abstract[74]|person[76]	new[74]|new[76]	_	_
12-9	1586-1591	other	abstract[74]|person[76]	new[74]|new[76]	_	_
12-10	1592-1599	members	abstract[74]|person[76]	new[74]|new[76]	_	_
12-11	1600-1602	of	abstract[74]|person[76]	new[74]|new[76]	_	_
12-12	1603-1606	the	abstract[74]|person[76]|substance[77]	new[74]|new[76]|new[77]	appos	12-16[0_77]
12-13	1607-1614	Nuclear	abstract[74]|person[76]|substance[77]	new[74]|new[76]|new[77]	_	_
12-14	1615-1623	Receptor	abstract[74]|person[76]|substance[77]	new[74]|new[76]|new[77]	_	_
12-15	1624-1625	(	_	_	_	_
12-16	1626-1628	NR	substance	giv	coref	14-40[115_0]
12-17	1629-1630	)	_	_	_	_
12-18	1631-1642	superfamily	person	new	_	_
12-19	1643-1644	,	_	_	_	_
12-20	1645-1647	is	_	_	_	_
12-21	1648-1651	not	_	_	_	_
12-22	1652-1656	just	_	_	_	_
12-23	1657-1666	regulated	_	_	_	_
12-24	1667-1669	by	_	_	_	_
12-25	1670-1676	ligand	organization|event[81]	new|new[81]	appos|coref|appos|coref	12-28[83_81]|14-65|12-28[83_81]|14-65
12-26	1677-1692	bioavailability	event[81]	new[81]	_	_
12-27	1693-1694	;	_	_	_	_
12-28	1695-1704	chromatin	substance|abstract[83]	new|giv[83]	coref|coref	22-4[196_83]|22-4[196_83]
12-29	1705-1716	environment	abstract[83]	giv[83]	_	_
12-30	1717-1718	,	abstract[83]	giv[83]	_	_
12-31	1719-1729	cross-talk	abstract[83]	giv[83]	_	_
12-32	1730-1733	and	abstract[83]	giv[83]	_	_
12-33	1734-1745	competition	abstract[83]	giv[83]	_	_
12-34	1746-1749	for	abstract[83]	giv[83]	_	_
12-35	1750-1758	response	abstract[83]|abstract|abstract[85]	giv[83]|new|giv[85]	_	_
12-36	1759-1766	element	abstract[83]|abstract[85]	giv[83]|giv[85]	_	_
12-37	1767-1774	binding	_	_	_	_
12-38	1775-1779	with	_	_	_	_
12-39	1780-1785	other	abstract[86]	new[86]	_	_
12-40	1786-1789	NRs	abstract[86]	new[86]	_	_
12-41	1790-1791	,	_	_	_	_
12-42	1792-1794	as	_	_	_	_
12-43	1795-1799	well	_	_	_	_
12-44	1800-1802	as	_	_	_	_
12-45	1803-1808	cell-	abstract[87]	new[87]	_	_
12-46	1809-1812	and	abstract[87]	new[87]	_	_
12-47	1813-1824	tissue-type	abstract[87]	new[87]	_	_
12-48	1825-1834	dependent	abstract[87]	new[87]	_	_
12-49	1835-1845	expression	abstract[87]	new[87]	_	_
12-50	1846-1848	of	abstract[87]	new[87]	_	_
12-51	1849-1858	cofactors	abstract[87]|substance	new[87]|new	_	_
12-52	1859-1862	are	_	_	_	_
12-53	1863-1867	also	_	_	_	_
12-54	1868-1871	key	abstract[89]	new[89]	_	_
12-55	1872-1881	mediators	abstract[89]	new[89]	_	_
12-56	1882-1883	.	_	_	_	_

#Text=For example , the expression of corepressors such as NCOR1 and NCOR2/SMRT determine how several cancers respond to nutritive ligands .
13-1	1884-1887	For	_	_	_	_
13-2	1888-1895	example	_	_	_	_
13-3	1896-1897	,	_	_	_	_
13-4	1898-1901	the	abstract[90]	new[90]	coref	22-14[202_90]
13-5	1902-1912	expression	abstract[90]	new[90]	_	_
13-6	1913-1915	of	abstract[90]	new[90]	_	_
13-7	1916-1928	corepressors	abstract[90]|abstract[91]	new[90]|new[91]	coref	14-11[99_91]
13-8	1929-1933	such	abstract[90]|abstract[91]	new[90]|new[91]	_	_
13-9	1934-1936	as	abstract[90]|abstract[91]	new[90]|new[91]	_	_
13-10	1937-1942	NCOR1	abstract[90]|abstract[91]|abstract	new[90]|new[91]|new	coref	14-13
13-11	1943-1946	and	abstract[90]|abstract[91]	new[90]|new[91]	_	_
13-12	1947-1957	NCOR2/SMRT	abstract[90]|abstract[91]|organization	new[90]|new[91]|new	_	_
13-13	1958-1967	determine	_	_	_	_
13-14	1968-1971	how	_	_	_	_
13-15	1972-1979	several	abstract[94]	new[94]	_	_
13-16	1980-1987	cancers	abstract[94]	new[94]	_	_
13-17	1988-1995	respond	_	_	_	_
13-18	1996-1998	to	_	_	_	_
13-19	1999-2008	nutritive	substance[95]	new[95]	_	_
13-20	2009-2016	ligands	substance[95]	new[95]	_	_
13-21	2017-2018	.	_	_	_	_

#Text=LXRA has a 100-fold higher binding affinity than LXRB for the corepressors NCOR1 and NCOR2 and deregulation of these corepressors allows prostate and bladder cancer cells to evade cancer suppressive signals of Vitamin D ( through repression of Vitamin D Receptor ( VDR ) ) and omega-3 fatty acids ( through repression of peroxisome proliferator-activated receptors ( PPARs ) ) by impairing sensitivity to ligand .
14-1	2019-2023	LXRA	place	giv	_	_
14-2	2024-2027	has	_	_	_	_
14-3	2028-2029	a	abstract[97]	new[97]	_	_
14-4	2030-2038	100-fold	abstract[97]	new[97]	_	_
14-5	2039-2045	higher	abstract[97]	new[97]	_	_
14-6	2046-2053	binding	abstract[97]	new[97]	_	_
14-7	2054-2062	affinity	abstract[97]	new[97]	_	_
14-8	2063-2067	than	abstract[97]	new[97]	_	_
14-9	2068-2072	LXRB	abstract[97]|abstract[98]	new[97]|giv[98]	_	_
14-10	2073-2076	for	abstract[97]|abstract[98]	new[97]|giv[98]	_	_
14-11	2077-2080	the	abstract[97]|abstract[98]|abstract[99]	new[97]|giv[98]|giv[99]	coref	14-19[103_99]
14-12	2081-2093	corepressors	abstract[97]|abstract[98]|abstract[99]	new[97]|giv[98]|giv[99]	_	_
14-13	2094-2099	NCOR1	abstract	giv	_	_
14-14	2100-2103	and	_	_	_	_
14-15	2104-2109	NCOR2	organization	new	_	_
14-16	2110-2113	and	_	_	_	_
14-17	2114-2126	deregulation	event[102]	new[102]	_	_
14-18	2127-2129	of	event[102]	new[102]	_	_
14-19	2130-2135	these	event[102]|abstract[103]	new[102]|giv[103]	_	_
14-20	2136-2148	corepressors	event[102]|abstract[103]	new[102]|giv[103]	_	_
14-21	2149-2155	allows	_	_	_	_
14-22	2156-2164	prostate	place	new	_	_
14-23	2165-2168	and	_	_	_	_
14-24	2169-2176	bladder	object|object[107]	new|new[107]	coref|coref	19-19[168_107]|19-19[168_107]
14-25	2177-2183	cancer	abstract|object[107]	giv|new[107]	coref	14-29
14-26	2184-2189	cells	object[107]	new[107]	_	_
14-27	2190-2192	to	_	_	_	_
14-28	2193-2198	evade	_	_	_	_
14-29	2199-2205	cancer	abstract	giv	coref	16-2
14-30	2206-2217	suppressive	abstract[109]	new[109]	_	_
14-31	2218-2225	signals	abstract[109]	new[109]	_	_
14-32	2226-2228	of	abstract[109]	new[109]	_	_
14-33	2229-2236	Vitamin	abstract[109]|substance|person[111]	new[109]|new|new[111]	coref|coref|coref|coref	14-39|14-40[0_111]|14-39|14-40[0_111]
14-34	2237-2238	D	abstract[109]|person[111]	new[109]|new[111]	_	_
14-35	2239-2240	(	abstract[109]	new[109]	_	_
14-36	2241-2248	through	abstract[109]	new[109]	_	_
14-37	2249-2259	repression	abstract[109]|event[112]	new[109]|new[112]	_	_
14-38	2260-2262	of	abstract[109]|event[112]	new[109]|new[112]	_	_
14-39	2263-2270	Vitamin	abstract[109]|event[112]|substance	new[109]|new[112]|giv	_	_
14-40	2271-2272	D	abstract[109]|event[112]|person|substance[115]	new[109]|new[112]|giv|giv[115]	coref|coref	18-2[154_115]|18-2[154_115]
14-41	2273-2281	Receptor	abstract[109]|event[112]|substance[115]	new[109]|new[112]|giv[115]	_	_
14-42	2282-2283	(	abstract[109]	new[109]	_	_
14-43	2284-2287	VDR	abstract[109]|place	new[109]|new	_	_
14-44	2288-2289	)	abstract[109]	new[109]	_	_
14-45	2290-2291	)	abstract[109]	new[109]	_	_
14-46	2292-2295	and	abstract[109]	new[109]	_	_
14-47	2296-2303	omega-3	abstract[109]|substance[117]	new[109]|giv[117]	_	_
14-48	2304-2309	fatty	abstract[109]|substance[117]	new[109]|giv[117]	_	_
14-49	2310-2315	acids	abstract[109]|substance[117]	new[109]|giv[117]	_	_
14-50	2316-2317	(	abstract[109]|substance[117]	new[109]|giv[117]	_	_
14-51	2318-2325	through	abstract[109]|substance[117]	new[109]|giv[117]	_	_
14-52	2326-2336	repression	abstract[109]|substance[117]|event[118]	new[109]|giv[117]|new[118]	_	_
14-53	2337-2339	of	abstract[109]|substance[117]|event[118]	new[109]|giv[117]|new[118]	_	_
14-54	2340-2350	peroxisome	abstract[109]|substance[117]|event[118]|abstract|abstract[120]	new[109]|giv[117]|new[118]|new|new[120]	appos|appos	14-58[0_120]|14-58[0_120]
14-55	2351-2373	proliferator-activated	abstract[109]|substance[117]|event[118]|abstract[120]	new[109]|giv[117]|new[118]|new[120]	_	_
14-56	2374-2383	receptors	abstract[109]|substance[117]|event[118]|abstract[120]	new[109]|giv[117]|new[118]|new[120]	_	_
14-57	2384-2385	(	_	_	_	_
14-58	2386-2391	PPARs	abstract	giv	_	_
14-59	2392-2393	)	_	_	_	_
14-60	2394-2395	)	_	_	_	_
14-61	2396-2398	by	_	_	_	_
14-62	2399-2408	impairing	_	_	_	_
14-63	2409-2420	sensitivity	abstract[122]	new[122]	_	_
14-64	2421-2423	to	abstract[122]	new[122]	_	_
14-65	2424-2430	ligand	abstract[122]|organization	new[122]|giv	coref	21-5
14-66	2431-2432	.	_	_	_	_

#Text=Simply measuring scOHC concentrations does not sufficiently determine their contributions to LXR signalling ; concentration and activation potential should be assessed in combination .
15-1	2433-2439	Simply	_	_	_	_
15-2	2440-2449	measuring	_	_	_	_
15-3	2450-2455	scOHC	substance|animal[125]	giv|giv[125]	ana|coref|ana|coref	15-9[0_125]|18-12|15-9[0_125]|18-12
15-4	2456-2470	concentrations	animal[125]	giv[125]	_	_
15-5	2471-2475	does	_	_	_	_
15-6	2476-2479	not	_	_	_	_
15-7	2480-2492	sufficiently	_	_	_	_
15-8	2493-2502	determine	_	_	_	_
15-9	2503-2508	their	animal|abstract[127]	giv|new[127]	_	_
15-10	2509-2522	contributions	abstract[127]	new[127]	_	_
15-11	2523-2525	to	abstract[127]	new[127]	_	_
15-12	2526-2529	LXR	abstract[127]|abstract|abstract[129]	new[127]|giv|giv[129]	coref|coref|coref|coref	16-9[0_129]|21-4|16-9[0_129]|21-4
15-13	2530-2540	signalling	abstract[127]|abstract[129]	new[127]|giv[129]	_	_
15-14	2541-2542	;	_	_	_	_
15-15	2543-2556	concentration	substance	new	_	_
15-16	2557-2560	and	_	_	_	_
15-17	2561-2571	activation	abstract|abstract[132]	new|new[132]	coref|coref|coref|coref	22-7|22-7[198_132]|22-7|22-7[198_132]
15-18	2572-2581	potential	abstract[132]	new[132]	_	_
15-19	2582-2588	should	_	_	_	_
15-20	2589-2591	be	_	_	_	_
15-21	2592-2600	assessed	_	_	_	_
15-22	2601-2603	in	_	_	_	_
15-23	2604-2615	combination	abstract	new	_	_
15-24	2616-2617	.	_	_	_	_

#Text=In cancer , the function of the scOHC-LXR signalling axis appears site specific as both tumour suppressive and promoting roles have been described .
16-1	2618-2620	In	_	_	_	_
16-2	2621-2627	cancer	abstract	giv	coref	17-16[148_0]
16-3	2628-2629	,	_	_	_	_
16-4	2630-2633	the	abstract[135]	new[135]	_	_
16-5	2634-2642	function	abstract[135]	new[135]	_	_
16-6	2643-2645	of	abstract[135]	new[135]	_	_
16-7	2646-2649	the	abstract[135]|abstract[138]	new[135]|new[138]	_	_
16-8	2650-2659	scOHC-LXR	abstract[135]|object|abstract[138]	new[135]|new|new[138]	coref	17-4
16-9	2660-2670	signalling	abstract[135]|abstract|abstract[138]	new[135]|giv|new[138]	coref	17-4[143_0]
16-10	2671-2675	axis	abstract[135]|abstract[138]	new[135]|new[138]	_	_
16-11	2676-2683	appears	_	_	_	_
16-12	2684-2688	site	abstract[139]	new[139]	_	_
16-13	2689-2697	specific	abstract[139]	new[139]	_	_
16-14	2698-2700	as	_	_	_	_
16-15	2701-2705	both	abstract[140]|abstract[141]	new[140]|new[141]	coref|coref|coref|coref	21-29[0_140]|23-37[216_141]|21-29[0_140]|23-37[216_141]
16-16	2706-2712	tumour	abstract[140]|abstract[141]	new[140]|new[141]	_	_
16-17	2713-2724	suppressive	abstract[141]	new[141]	_	_
16-18	2725-2728	and	abstract[141]	new[141]	_	_
16-19	2729-2738	promoting	abstract[141]	new[141]	_	_
16-20	2739-2744	roles	abstract[141]	new[141]	_	_
16-21	2745-2749	have	_	_	_	_
16-22	2750-2754	been	_	_	_	_
16-23	2755-2764	described	_	_	_	_
16-24	2765-2766	.	_	_	_	_

#Text=For example , scOHC-LXR signalling impairs invasion and angiogenesis in melanoma and is anti-proliferative in lung cancer in vivo , as it is in almost every cancer cell line studied in vitro .
17-1	2767-2770	For	_	_	_	_
17-2	2771-2778	example	_	_	_	_
17-3	2779-2780	,	_	_	_	_
17-4	2781-2790	scOHC-LXR	abstract|abstract[143]	giv|giv[143]	coref|coref|coref|coref	23-29|23-29[214_143]|23-29|23-29[214_143]
17-5	2791-2801	signalling	abstract[143]	giv[143]	_	_
17-6	2802-2809	impairs	_	_	_	_
17-7	2810-2818	invasion	event	new	_	_
17-8	2819-2822	and	_	_	_	_
17-9	2823-2835	angiogenesis	abstract	new	_	_
17-10	2836-2838	in	_	_	_	_
17-11	2839-2847	melanoma	abstract	new	_	_
17-12	2848-2851	and	_	_	_	_
17-13	2852-2854	is	_	_	_	_
17-14	2855-2873	anti-proliferative	_	_	_	_
17-15	2874-2876	in	_	_	_	_
17-16	2877-2881	lung	object|abstract[148]	new|giv[148]	ana|ana	17-22[0_148]|17-22[0_148]
17-17	2882-2888	cancer	abstract[148]	giv[148]	_	_
17-18	2889-2891	in	abstract[148]	giv[148]	_	_
17-19	2892-2896	vivo	abstract[148]	giv[148]	_	_
17-20	2897-2898	,	_	_	_	_
17-21	2899-2901	as	_	_	_	_
17-22	2902-2904	it	abstract	giv	coref	17-27
17-23	2905-2907	is	_	_	_	_
17-24	2908-2910	in	_	_	_	_
17-25	2911-2917	almost	object[152]	new[152]	_	_
17-26	2918-2923	every	object[152]	new[152]	_	_
17-27	2924-2930	cancer	abstract|object[152]	giv|new[152]	coref	18-6[156_0]
17-28	2931-2935	cell	object|object[152]	new|new[152]	_	_
17-29	2936-2940	line	object[152]	new[152]	_	_
17-30	2941-2948	studied	_	_	_	_
17-31	2949-2951	in	_	_	_	_
17-32	2952-2957	vitro	_	_	_	_
17-33	2958-2959	.	_	_	_	_

#Text=In Oestrogen Receptor ( ER)-positive Breast Cancer ( BCa ) however 26-OHC promotes growth in vivo via ER-alpha .
18-1	2960-2962	In	_	_	_	_
18-2	2963-2972	Oestrogen	substance|substance[154]	new|giv[154]	coref|coref	23-12[0_154]|23-12[0_154]
18-3	2973-2981	Receptor	substance[154]	giv[154]	_	_
18-4	2982-2983	(	_	_	_	_
18-5	2984-2996	ER)-positive	person	new	_	_
18-6	2997-3003	Breast	abstract[156]	giv[156]	coref	23-44[0_156]
18-7	3004-3010	Cancer	abstract[156]	giv[156]	_	_
18-8	3011-3012	(	_	_	_	_
18-9	3013-3016	BCa	object	new	coref	19-3
18-10	3017-3018	)	_	_	_	_
18-11	3019-3026	however	_	_	_	_
18-12	3027-3033	26-OHC	substance	giv	coref	19-3[163_0]
18-13	3034-3042	promotes	_	_	_	_
18-14	3043-3049	growth	abstract[159]	new[159]	_	_
18-15	3050-3052	in	abstract[159]	new[159]	_	_
18-16	3053-3057	vivo	abstract[159]	new[159]	_	_
18-17	3058-3061	via	abstract[159]	new[159]	_	_
18-18	3062-3070	ER-alpha	abstract[159]|substance	new[159]|new	_	_
18-19	3071-3072	.	_	_	_	_

#Text=In ER-negative BCa 26-OHC drives the epithelial-to-mesenchymal transition and promotes colonization of metastatic sites in through mobilization of γδ-T cells .
19-1	3073-3075	In	_	_	_	_
19-2	3076-3087	ER-negative	person	new	ana	20-31[177_0]
19-3	3088-3091	BCa	object|substance[163]	giv|giv[163]	coref|coref|coref|coref	20-10[171_0]|22-4[0_163]|20-10[171_0]|22-4[0_163]
19-4	3092-3098	26-OHC	substance[163]	giv[163]	_	_
19-5	3099-3105	drives	_	_	_	_
19-6	3106-3109	the	event[164]	new[164]	_	_
19-7	3110-3135	epithelial-to-mesenchymal	event[164]	new[164]	_	_
19-8	3136-3146	transition	event[164]	new[164]	_	_
19-9	3147-3150	and	_	_	_	_
19-10	3151-3159	promotes	_	_	_	_
19-11	3160-3172	colonization	event[165]	new[165]	_	_
19-12	3173-3175	of	event[165]	new[165]	_	_
19-13	3176-3186	metastatic	event[165]|place[166]	new[165]|new[166]	_	_
19-14	3187-3192	sites	event[165]|place[166]	new[165]|new[166]	_	_
19-15	3193-3195	in	_	_	_	_
19-16	3196-3203	through	_	_	_	_
19-17	3204-3216	mobilization	event[167]	new[167]	_	_
19-18	3217-3219	of	event[167]	new[167]	_	_
19-19	3220-3224	γδ-T	event[167]|object[168]	new[167]|giv[168]	_	_
19-20	3225-3230	cells	event[167]|object[168]	new[167]|giv[168]	_	_
19-21	3231-3232	.	_	_	_	_

#Text=Furthermore , concentrations of several scOHCs are altered in BCa relative to normal tissue , and 25-OHC is elevated in the circulation of BCa patients who have relapsed compared to those with primary disease .
20-1	3233-3244	Furthermore	_	_	_	_
20-2	3245-3246	,	_	_	_	_
20-3	3247-3261	concentrations	animal[169]	new[169]	coref	21-26[190_169]
20-4	3262-3264	of	animal[169]	new[169]	_	_
20-5	3265-3272	several	animal[169]|object[170]	new[169]|giv[170]	_	_
20-6	3273-3279	scOHCs	animal[169]|object[170]	new[169]|giv[170]	_	_
20-7	3280-3283	are	_	_	_	_
20-8	3284-3291	altered	_	_	_	_
20-9	3292-3294	in	_	_	_	_
20-10	3295-3298	BCa	object[171]	giv[171]	coref	20-24[0_171]
20-11	3299-3307	relative	object[171]	giv[171]	_	_
20-12	3308-3310	to	_	_	_	_
20-13	3311-3317	normal	object[172]	giv[172]	_	_
20-14	3318-3324	tissue	object[172]	giv[172]	_	_
20-15	3325-3326	,	_	_	_	_
20-16	3327-3330	and	_	_	_	_
20-17	3331-3337	25-OHC	quantity	new	_	_
20-18	3338-3340	is	_	_	_	_
20-19	3341-3349	elevated	_	_	_	_
20-20	3350-3352	in	_	_	_	_
20-21	3353-3356	the	abstract[174]	new[174]	_	_
20-22	3357-3368	circulation	abstract[174]	new[174]	_	_
20-23	3369-3371	of	abstract[174]	new[174]	_	_
20-24	3372-3375	BCa	abstract[174]|abstract|person[176]	new[174]|giv|new[176]	coref|coref|coref|coref	21-10|23-49[0_176]|21-10|23-49[0_176]
20-25	3376-3384	patients	abstract[174]|person[176]	new[174]|new[176]	_	_
20-26	3385-3388	who	_	_	_	_
20-27	3389-3393	have	_	_	_	_
20-28	3394-3402	relapsed	_	_	_	_
20-29	3403-3411	compared	_	_	_	_
20-30	3412-3414	to	_	_	_	_
20-31	3415-3420	those	person[177]	giv[177]	_	_
20-32	3421-3425	with	person[177]	giv[177]	_	_
20-33	3426-3433	primary	person[177]|abstract[178]	giv[177]|giv[178]	_	_
20-34	3434-3441	disease	person[177]|abstract[178]	giv[177]|giv[178]	_	_
20-35	3442-3443	.	_	_	_	_

#Text=We recently evaluated LXR ligand bio-availability in a small BCa cohort and found large inter tumoural heterogeneity in oxysterol content , but no difference in ligand concentrations between tumour subtypes .
21-1	3444-3446	We	person	acc	_	_
21-2	3447-3455	recently	_	_	_	_
21-3	3456-3465	evaluated	_	_	_	_
21-4	3466-3469	LXR	abstract|abstract[182]	giv|new[182]	_	_
21-5	3470-3476	ligand	organization|abstract[182]	giv|new[182]	coref	21-26
21-6	3477-3493	bio-availability	abstract[182]	new[182]	_	_
21-7	3494-3496	in	_	_	_	_
21-8	3497-3498	a	person[184]	new[184]	_	_
21-9	3499-3504	small	person[184]	new[184]	_	_
21-10	3505-3508	BCa	abstract|person[184]	giv|new[184]	coref	22-18
21-11	3509-3515	cohort	person[184]	new[184]	_	_
21-12	3516-3519	and	_	_	_	_
21-13	3520-3525	found	_	_	_	_
21-14	3526-3531	large	abstract[185]	new[185]	_	_
21-15	3532-3537	inter	abstract[185]	new[185]	_	_
21-16	3538-3546	tumoural	abstract[185]	new[185]	_	_
21-17	3547-3560	heterogeneity	abstract[185]	new[185]	_	_
21-18	3561-3563	in	abstract[185]	new[185]	_	_
21-19	3564-3573	oxysterol	abstract[185]|abstract|abstract[187]	new[185]|new|new[187]	_	_
21-20	3574-3581	content	abstract[185]|abstract[187]	new[185]|new[187]	_	_
21-21	3582-3583	,	_	_	_	_
21-22	3584-3587	but	_	_	_	_
21-23	3588-3590	no	abstract[188]	giv[188]	_	_
21-24	3591-3601	difference	abstract[188]	giv[188]	_	_
21-25	3602-3604	in	abstract[188]	giv[188]	_	_
21-26	3605-3611	ligand	abstract[188]|organization|animal[190]	giv[188]|giv|giv[190]	_	_
21-27	3612-3626	concentrations	abstract[188]|animal[190]	giv[188]|giv[190]	_	_
21-28	3627-3634	between	abstract[188]|animal[190]	giv[188]|giv[190]	_	_
21-29	3635-3641	tumour	abstract[188]|animal[190]|abstract|abstract[192]	giv[188]|giv[190]|giv|giv[192]	coref|coref	22-18[204_192]|22-18[204_192]
21-30	3642-3650	subtypes	abstract[188]|animal[190]|abstract[192]	giv[188]|giv[190]|giv[192]	_	_
21-31	3651-3652	.	_	_	_	_

#Text=Systematic evaluation of scOHC bioavailability and activation potential , coupled with analysis of NR cofactor expression between BCa subtypes has not been performed previously .
22-1	3653-3663	Systematic	abstract[193]	new[193]	_	_
22-2	3664-3674	evaluation	abstract[193]	new[193]	_	_
22-3	3675-3677	of	abstract[193]	new[193]	_	_
22-4	3678-3683	scOHC	abstract[193]|abstract|abstract[195]|event[196]	new[193]|giv|new[195]|giv[196]	_	_
22-5	3684-3699	bioavailability	abstract[193]|abstract[195]|event[196]	new[193]|new[195]|giv[196]	_	_
22-6	3700-3703	and	abstract[193]|event[196]	new[193]|giv[196]	_	_
22-7	3704-3714	activation	abstract[193]|event[196]|abstract|abstract[198]	new[193]|giv[196]|giv|giv[198]	_	_
22-8	3715-3724	potential	abstract[193]|event[196]|abstract[198]	new[193]|giv[196]|giv[198]	_	_
22-9	3725-3726	,	_	_	_	_
22-10	3727-3734	coupled	_	_	_	_
22-11	3735-3739	with	_	_	_	_
22-12	3740-3748	analysis	abstract[199]	new[199]	_	_
22-13	3749-3751	of	abstract[199]	new[199]	_	_
22-14	3752-3754	NR	abstract[199]|person|abstract[202]	new[199]|new|giv[202]	_	_
22-15	3755-3763	cofactor	abstract[199]|person|abstract[202]	new[199]|new|giv[202]	_	_
22-16	3764-3774	expression	abstract[199]|abstract[202]	new[199]|giv[202]	_	_
22-17	3775-3782	between	abstract[199]|abstract[202]	new[199]|giv[202]	_	_
22-18	3783-3786	BCa	abstract[199]|abstract[202]|abstract|abstract[204]	new[199]|giv[202]|giv|giv[204]	coref|coref|coref|coref	23-9|23-24[212_204]|23-9|23-24[212_204]
22-19	3787-3795	subtypes	abstract[199]|abstract[202]|abstract[204]	new[199]|giv[202]|giv[204]	_	_
22-20	3796-3799	has	_	_	_	_
22-21	3800-3803	not	_	_	_	_
22-22	3804-3808	been	_	_	_	_
22-23	3809-3818	performed	_	_	_	_
22-24	3819-3829	previously	_	_	_	_
22-25	3830-3831	.	_	_	_	_

#Text=Given the prognostic and therapeutic value of stratifying BCa by hormone receptor status , further delineation of the pathways that are altered between these subtypes , such as scOHC-LXR signalling , may help advance understanding about the emerging roles of cholesterol metabolism in cancer and improve outcomes for patients .
23-1	3832-3837	Given	_	_	_	_
23-2	3838-3841	the	abstract[205]	new[205]	_	_
23-3	3842-3852	prognostic	abstract[205]	new[205]	_	_
23-4	3853-3856	and	abstract[205]	new[205]	_	_
23-5	3857-3868	therapeutic	abstract[205]	new[205]	_	_
23-6	3869-3874	value	abstract[205]	new[205]	_	_
23-7	3875-3877	of	_	_	_	_
23-8	3878-3889	stratifying	_	_	_	_
23-9	3890-3893	BCa	object	giv	_	_
23-10	3894-3896	by	_	_	_	_
23-11	3897-3904	hormone	substance|abstract[209]	new|giv[209]	_	_
23-12	3905-3913	receptor	substance|abstract[209]	giv|giv[209]	_	_
23-13	3914-3920	status	abstract[209]	giv[209]	_	_
23-14	3921-3922	,	_	_	_	_
23-15	3923-3930	further	abstract[210]	new[210]	_	_
23-16	3931-3942	delineation	abstract[210]	new[210]	_	_
23-17	3943-3945	of	abstract[210]	new[210]	_	_
23-18	3946-3949	the	abstract[210]|abstract[211]	new[210]|new[211]	_	_
23-19	3950-3958	pathways	abstract[210]|abstract[211]	new[210]|new[211]	_	_
23-20	3959-3963	that	_	_	_	_
23-21	3964-3967	are	_	_	_	_
23-22	3968-3975	altered	_	_	_	_
23-23	3976-3983	between	_	_	_	_
23-24	3984-3989	these	abstract[212]	giv[212]	_	_
23-25	3990-3998	subtypes	abstract[212]	giv[212]	_	_
23-26	3999-4000	,	abstract[212]	giv[212]	_	_
23-27	4001-4005	such	abstract[212]	giv[212]	_	_
23-28	4006-4008	as	abstract[212]	giv[212]	_	_
23-29	4009-4018	scOHC-LXR	abstract[212]|abstract|abstract[214]	giv[212]|giv|giv[214]	_	_
23-30	4019-4029	signalling	abstract[212]|abstract[214]	giv[212]|giv[214]	_	_
23-31	4030-4031	,	_	_	_	_
23-32	4032-4035	may	_	_	_	_
23-33	4036-4040	help	_	_	_	_
23-34	4041-4048	advance	_	_	_	_
23-35	4049-4062	understanding	abstract[215]	new[215]	_	_
23-36	4063-4068	about	abstract[215]	new[215]	_	_
23-37	4069-4072	the	abstract[215]|abstract[216]	new[215]|giv[216]	_	_
23-38	4073-4081	emerging	abstract[215]|abstract[216]	new[215]|giv[216]	_	_
23-39	4082-4087	roles	abstract[215]|abstract[216]	new[215]|giv[216]	_	_
23-40	4088-4090	of	abstract[215]|abstract[216]	new[215]|giv[216]	_	_
23-41	4091-4102	cholesterol	abstract[215]|abstract[216]|substance|abstract[218]	new[215]|giv[216]|giv|giv[218]	_	_
23-42	4103-4113	metabolism	abstract[215]|abstract[216]|abstract[218]	new[215]|giv[216]|giv[218]	_	_
23-43	4114-4116	in	abstract[215]|abstract[216]|abstract[218]	new[215]|giv[216]|giv[218]	_	_
23-44	4117-4123	cancer	abstract[215]|abstract[216]|abstract[218]|abstract	new[215]|giv[216]|giv[218]|giv	_	_
23-45	4124-4127	and	_	_	_	_
23-46	4128-4135	improve	_	_	_	_
23-47	4136-4144	outcomes	abstract	new	_	_
23-48	4145-4148	for	_	_	_	_
23-49	4149-4157	patients	person	giv	_	_
23-50	4158-4159	.	_	_	_	_
